Atreca, Inc.
Atreca, Inc. (BCEL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BCEL · as of Jun 9, 2026
Key Statistics
Explore Atreca, Inc. Data
bcel stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 50.0%
The BCEL analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +4344.44% upside from the current price of $0.09.
Competitors & Peers
bcel competitorsBCEL
AFMD
ARAV
GMDA
GRTS
IDRAStock Performance
Full HistoryAbout Atreca, Inc.
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic,…
what is atreca, inc. · bcel stock overview · atreca, inc. company profile · who is atreca, inc. ceo · bcel NASDAQ · atreca, inc. headquarters · atreca, inc. business segments
About Stock Overview & Key Data
Atreca, Inc. (BCEL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 20, 2019. As of the latest trading session, BCEL stock price is $0.09, with a market capitalization of $3.6M. The stock has returned -90.72% over the past 12 months and -31.14% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Atreca, Inc. stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2022, Atreca, Inc. reported revenue of $770000.00 and net income of -$97.2M. For detailed data — including Atreca, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Atreca, Inc. (BCEL) stock price is $0.09. The stock is traded on NASDAQ under the ticker symbol BCEL. The 52-week range is $0.05 – $1.20.